An observational study in Osteoarthritis,Knee, Osteoarthritis Knees Both and Osteoarthritis Hip, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by University of Utah · Observational
Among 796 studies in Osteoarthritis, Knee with a site in United States — 110 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.
Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 54th largest by enrollment of the 101 observational ones that give a count, is one of 49 that started in 2022, is one of 101 observational ones, and was the 739th registered.
3,292 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →110 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
VA Office of Research and Development · Sites in United States
Ages 45–75
Benedict Alter · Sites in United States
Ages 45–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 382 Osteoarthritis, Knee studies recruiting now, 176 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
796 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 60 · Phase 2 146 · Phase 3 89 · Phase 4 59
First in 1977; this study’s year is marked. 49 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is close to the median of 100 across 486 observational studies indexed under Osteoarthritis, Knee.
Median enrollment 72 across the 691 interventional studies, 100 across the 101 observational. Of the 565 that completed or were terminated, 247 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
265 of 796 have an industry lead sponsor. The 10 most frequent:
University of Utah is the lead sponsor of 994 studies on the registry; 175 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.
University of Utah has 6 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
53 of the studies in Osteoarthritis, Knee with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226258Phase 3Saol Therapeutics IncPhase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain | 2026-11-30 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT04368806Phase 3Nature Cell Co. Ltd.A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | 2027-08-06 |
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
Among the 796 studies in Osteoarthritis, Knee with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic musculoskeletal conditions (chronic low back pain, knee osteoarthritis, hip osteoarthritis) are the most common causes of long-term disability resulting in a loss of quality-of life for affected individuals and high costs for society. Regular physical activity can reduce disability and improve quality-of-life but can be challenging in the presence of pain and impaired function. This proposal addresses an urgent need for interventions that support physical activity in this population by leveraging the physical therapy intervention to address symptoms of chronic musculoskeletal conditions and support long-term physical activity engagement.
Coach2Move is a patient-centered physical therapy intervention that has demonstrated success in changing physical activity in adults with chronic medical conditions. Coach2Move has only been delivered in the Netherlands with older adults at risk of frailty. It is unclear if it is feasible to deliver this intervention within a U.S. health system and if it would be effective for older adults with chronic MSK conditions. The objective of this research is to adapt and implement the Coach2Move intervention among mid-life and older adults with chronic MSK conditions in a U.S. health care system.
The investigators will do this through the following specific aims:
Aim 1: Adapt the Coach2Move intervention for mid-life and older adults with chronic MSK conditions.
Using a systematic process, intervention mapping, investigators will adapt the Coach2Move training, patient and provider materials to incorporate best evidence for chronic low back pain, and hip/knee osteoarthritis. The investigators will use the logic model from the original Coach2Move program to identify changes necessary for delivery to this population and in the U.S. health system. The adaptation team will include the Coach2Move developers, 2 physical therapists and 2 patient-representatives.
Aim 2: Assess the impact of implementing Coach2Move on patient-level physical activity and function.
With a single group clinical cohort of 104 patients, investigators will examine the impact of the adapted Coach2Move on PA and function 6-months after initiating PT. Investigators will measure implementation with fidelity, dose and reach. Investigators will examine the association between Coach2Move fidelity and dose on PA using regression models and examine reach descriptively across clinics and patient demographics.
Aim 3: Identify Coach2Move implementation barriers and facilitators from both clinician and patient perspectives.
Investigators will evaluate patient and clinician experiences with Coach2Move through semi-structured patient interviews and a clinician focus group. Using interviews with 30 patients receiving the Coach2Move intervention, we will explore the patient experience, perceived burden of the program, and health beliefs. With clinician interviews we will examine barriers and facilitators to implementing Coach2Move.
Patients schedule for physical therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will work with physical therapists to identify motivation for physical activity and related goals. Together the patient and the physical therapists will identify ways to address the patient\'s medical condition and how to adapt physical activity if needed given their medical condition(s). Physical therapists will work with a person-centered approach tailoring rehabilitation to the individual patient goals, medical condition, social support, and self-efficacy.
Self-reported physical activity: International Physical Activity Questionnaire
moderate-vigorous minutes of physical activity per week
Time frame: 6 months
Physical activity as measured by accelerometer (Fitbit)
moderate-vigorous minutes of physical activity per week
Time frame: 6 months
PROMIS Physical Function
Computer adaptive version 2.0; self-reported physical function
Time frame: 6 months
PROMIS Pain Interference
Computer adaptive version 1.1; self-reported activity limitations due to pain
Time frame: 6 months
Physical activity self-regulation
Self-reported ability to work through potential barriers to physical activity
Time frame: 6 months
PROMIS Self-Efficacy to Manage Symptoms
Computer adaptive version 1.0; self-reported confidence in managing symptoms of chronic conditions
Time frame: 6 months
Fidelity
Chart review of quality indicators for delivering Coach2Move
Time frame: 8 weeks
Reach
Measure of number of patients receiving Coach2Move divided by patients in the health system appropriate for Coach2Move
Time frame: 6 months
Adoption
Proportion of eligible physical therapists that agree to train in Coach2Move and complete training.
Time frame: 8 weeks
Dose
Number of physical therapy visits
Time frame: 8 weeks
Working Alliance Theory of Change Inventory
Patient reported measure of perceived alliance with their physical therapist
Time frame: 8 weeks
Plan to share: No
Ran from Feb 2022 to primary completion in Apr 2024, 25 months.
Of 179 non-industry observational studies under Osteoarthritis, Knee, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's 25 months is close to that.
Counting every sponsor, half of 220 studies reached it within 24 months; a quarter within 14 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.